高盛料印度股市市值三年內升至逾5萬億美元 爲全球第五大
高盛估計,隨着投資者把資金投放於印度股市,印度股市市值可在三年內由3.5萬億美元升至逾5萬億美元,超越英國及中東,成爲全球第五大股市。
高盛指,印度初創今年上市集資額已達100億美元,高於過去3年總和。未來兩年上市公司情況料仍然強勁,在未來16個月內或會有最多150間私企上市,2至3年內新股上市將帶來近4,000億美元市值。
高盛估計,目前有最少67間印度初創估值超越10億美元成爲「獨角獸」,當中27間爲今年「獨角獸」新成員,大部分爲數碼經濟股份。高盛預計科技公司上市將改變印度資本市場及股指。(fc/W)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.